請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29259完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 郭應誠 | |
| dc.contributor.author | Chia-chen Chen | en |
| dc.contributor.author | 陳家真 | zh_TW |
| dc.date.accessioned | 2021-06-13T01:03:30Z | - |
| dc.date.available | 2007-09-01 | |
| dc.date.copyright | 2007-07-31 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-23 | |
| dc.identifier.citation | References
Ahima R. S. and Osei S. Y. (2004) Leptin signaling. Physiol Behav 81, 223-41. Almog B., Gold R., Tajima K., Dantes A., Salim K., Rubinstein M., Barkan D., Homburg R., Lessing J. B., Nevo N., Gertler A. and Amsterdam A. (2001) Leptin attenuates follicular apoptosis and accelerates the onset of puberty in immature rats. Mol Cell Endocrinol 183, 179-91. Ambrosini G., Nath A. K., Sierra-Honigmann M. R. and Flores-Riveros J. (2002) Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 277, 34601-9. Artwohl M., Roden M., Holzenbein T., Freudenthaler A., Waldhausl W. and Baumgartner-Parzer S. M. (2002) Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord 26, 577-80. Auersperg N., Edelson M. I., Mok S. C., Johnson S. W. and Hamilton T. C. (1998) The biology of ovarian cancer. Semin Oncol 25, 281-304. Bado A., Levasseur S., Attoub S., Kermorgant S., Laigneau J. P., Bortoluzzi M. N., Moizo L., Lehy T., Guerre-Millo M., Le Marchand-Brustel Y. and Lewin M. J. (1998) The stomach is a source of leptin. Nature 394, 790-3. Bataller R. and Brenner D. A. (2005) Liver fibrosis. J Clin Invest 115, 209-18. Beehler G. P., Sekhon M., Baker J. A., Teter B. E., McCann S. E., Rodabaugh K. J. and Moysich K. B. (2006) Risk of ovarian cancer associated with BMI varies by menopausal status. J Nutr 136, 2881-6. Bjorbaek C., Uotani S., da Silva B. and Flier J. S. (1997) Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 272, 32686-95. Blum W. F., Englaro P., Hanitsch S., Juul A., Hertel N. T., Muller J., Skakkebaek N. E., Heiman M. L., Birkett M., Attanasio A. M., Kiess W. and Rascher W. (1997) Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 82, 2904-10. Boelhauve M., Sinowatz F., Wolf E. and Paula-Lopes F. F. (2005) Maturation of bovine oocytes in the presence of leptin improves development and reduces apoptosis of in vitro-produced blastocysts. Biol Reprod 73, 737-44. Bouloumie A., Drexler H. C., Lafontan M. and Busse R. (1998) Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 83, 1059-66. Brann D. W., De Sevilla L., Zamorano P. L. and Mahesh V. B. (1999) Regulation of leptin gene expression and secretion by steroid hormones. Steroids 64, 659-63. Bray G. A. (2002) The underlying basis for obesity: relationship to cancer. J Nutr 132, 3451S-3455S. Briscoe C. P., Hanif S., Arch J. R. and Tadayyon M. (2001) Leptin receptor long-form signalling in a human liver cell line. Cytokine 14, 225-9. Buettner R., Mora L. B. and Jove R. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945-54. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M. and Rizzetto M. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-40. Calle E. E., Rodriguez C., Walker-Thurmond K. and Thun M. J. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348, 1625-38. Campfield L. A., Smith F. J., Guisez Y., Devos R. and Burn P. (1995) Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269, 546-9. Cao R., Brakenhielm E., Wahlestedt C., Thyberg J. and Cao Y. (2001) Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A 98, 6390-5. Carroll J. S., Swarbrick A., Musgrove E. A. and Sutherland R. L. (2002) Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 62, 3126-31. Catalano S., Marsico S., Giordano C., Mauro L., Rizza P., Panno M. L. and Ando S. (2003) Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278, 28668-76. Catalano S., Mauro L., Marsico S., Giordano C., Rizza P., Rago V., Montanaro D., Maggiolini M., Panno M. L. and Ando S. (2004) Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 279, 19908-15. Chen C., Chang Y. C., Liu C. L., Chang K. J. and Guo I. C. (2006a) Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21(WAF1/CIP1). Breast Cancer Res Treat 98, 121-32. Chen K., Li F., Li J., Cai H., Strom S., Bisello A., Kelley D. E., Friedman-Einat M., Skibinski G. A., McCrory M. A., Szalai A. J. and Zhao A. Z. (2006b) Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 12, 425-32. Choi J. H., Park S. H., Leung P. C. and Choi K. C. (2005) Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 90, 207-10. Cleary M. P., Juneja S. C., Phillips F. C., Hu X., Grande J. P. and Maihle N. J. (2004) Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 229, 182-93. Cleary M. P., Phillips F. C., Getzin S. C., Jacobson T. L., Jacobson M. K., Christensen T. A., Juneja S. C., Grande J. P. and Maihle N. J. (2003) Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 77, 205-15. Cohen B., Novick D. and Rubinstein M. (1996) Modulation of insulin activities by leptin. Science 274, 1185-8. Coleman D. L. (1973) Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 9, 294-8. Deming S. L., Nass S. J., Dickson R. B. and Trock B. J. (2000) C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83, 1688-95. Dieudonne M. N., Machinal-Quelin F., Serazin-Leroy V., Leneveu M. C., Pecquery R. and Giudicelli Y. (2002) Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 293, 622-8. Ding X., Saxena N. K., Lin S., Xu A., Srinivasan S. and Anania F. A. (2005) The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 166, 1655-69. Duan C., Li M. and Rui L. (2004) SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem 279, 43684-91. Dumitrescu R. G. and Cotarla I. (2005) Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med 9, 208-21. Dyer Z., Peltekian K. and van Zanten S. V. (2005) Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 22, 17-22. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W. and Vogelstein B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-25. Elinav E., Abd-Elnabi A., Pappo O., Bernstein I., Klein A., Engelhardt D., Rabbani E. and Ilan Y. (2006) Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol 44, 529-36. Fernando R. I. and Wimalasena J. (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15, 3266-84. Ferrer I. and Planas A. M. (2003) Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol 62, 329-39. Frankenberry K. A., Skinner H., Somasundar P., McFadden D. W. and Vona-Davis L. C. (2006) Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28, 985-93. Frankenberry K. A., Somasundar P., McFadden D. W. and Vona-Davis L. C. (2004) Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188, 560-5. Fruhbeck G. (2006) Intracellular signalling pathways activated by leptin. Biochem J 393, 7-20. Garofalo C., Sisci D. and Surmacz E. (2004) Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin Cancer Res 10, 6466-75. Garofalo C. and Surmacz E. (2006) Leptin and cancer. J Cell Physiol 207, 12-22. Gong D. W., Bi S., Pratley R. E. and Weintraub B. D. (1996) Genomic structure and promoter analysis of the human obese gene. J Biol Chem 271, 3971-4. Gonzalez L., Blanc J. F., Sa Cunha A., Rullier A., Saric J., Le Bail B., Balabaud C. and Bioulac-Sage P. (2004) Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin Liver Dis 24, 415-9. Gordeladze J. O., Drevon C. A., Syversen U. and Reseland J. E. (2002) Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 85, 825-36. Green D. R. and Kroemer G. (2004) The pathophysiology of mitochondrial cell death. Science 305, 626-9. Greenlee R. T., Hill-Harmon M. B., Murray T. and Thun M. (2001) Cancer statistics, 2001. CA Cancer J Clin 51, 15-36. Harada H. and Grant S. (2003) Apoptosis regulators. Rev Clin Exp Hematol 7, 117-38. Hardwick J. C., Van Den Brink G. R., Offerhaus G. J., Van Deventer S. J. and Peppelenbosch M. P. (2001) Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121, 79-90. Havel P. J., Kasim-Karakas S., Dubuc G. R., Mueller W. and Phinney S. D. (1996a) Gender differences in plasma leptin concentrations. Nat Med 2, 949-50. Havel P. J., Kasim-Karakas S., Mueller W., Johnson P. R., Gingerich R. L. and Stern J. S. (1996b) Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 81, 4406-13. Hegyi K., Fulop K., Kovacs K., Toth S. and Falus A. (2004) Leptin-induced signal transduction pathways. Cell Biol Int 28, 159-69. Heiser D., Labi V., Erlacher M. and Villunger A. (2004) The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol 39, 1125-35. Hoggard N., Hunter L., Duncan J. S., Williams L. M., Trayhurn P. and Mercer J. G. (1997) Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci U S A 94, 11073-8. Hsu H. T., Chang Y. C., Chiu Y. N., Liu C. L., Chang K. J. and Guo I. C. (2006) Leptin interferes with adrenocorticotropin/3',5'-cyclic adenosine monophosphate (cAMP) signaling, possibly through a Janus kinase 2-phosphatidylinositol 3-kinase/Akt-phosphodiesterase 3-cAMP pathway, to down-regulate cholesterol side-chain cleavage cytochrome P450 enzyme in human adrenocortical NCI-H295 cell line. J Clin Endocrinol Metab 91, 2761-9. Hu X., Juneja S. C., Maihle N. J. and Cleary M. P. (2002) Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94, 1704-11. Hui A. M., Makuuchi M. and Li X. (1998) Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 45, 1635-42. Husain S. S., Szabo I. L., Pai R., Soreghan B., Jones M. K. and Tarnawski A. S. (2001) MAPK (ERK2) kinase--a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci 69, 3045-54. Ioka A., Tsukuma H., Ajiki W. and Oshima A. (2003) Ovarian cancer incidence and survival by histologic type in Osaka, Japan. Cancer Sci 94, 292-6. Ishikawa M., Kitayama J. and Nagawa H. (2004) Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10, 4325-31. Jackson A. A. (2005) Integrating the ideas of life course across cellular, individual, and population levels in cancer causation. J Nutr 135, 2927S-2933S. Jockenhovel F., Blum W. F., Vogel E., Englaro P., Muller-Wieland D., Reinwein D., Rascher W. and Krone W. (1997) Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 82, 2510-3. Johnstone R. W., Ruefli A. A. and Lowe S. W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-64. Kanu A., Fain J. N., Bahouth S. W. and Cowan G. S., Jr. (2003) Regulation of leptin release by insulin, glucocorticoids, G(i)-coupled receptor agonists, and pertussis toxin in adipocytes and adipose tissue explants from obese humans in primary culture. Metabolism 52, 60-6. Key T., Appleby P., Barnes I. and Reeves G. (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94, 606-16. Key T. J., Allen N. E., Verkasalo P. K. and Banks E. (2001) Energy balance and cancer: the role of sex hormones. Proc Nutr Soc 60, 81-9. Knudsen K. E., Diehl J. A., Haiman C. A. and Knudsen E. S. (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25, 1620-8. Kroenke C. H., Chen W. Y., Rosner B. and Holmes M. D. (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23, 1370-8. Ktori C., Shepherd P. R. and O'Rourke L. (2003) TNF-alpha and leptin activate the alpha-isoform of class II phosphoinositide 3-kinase. Biochem Biophys Res Commun 306, 139-43. Kume K., Satomura K., Nishisho S., Kitaoka E., Yamanouchi K., Tobiume S. and Nagayama M. (2002) Potential role of leptin in endochondral ossification. J Histochem Cytochem 50, 159-69. Kuo M. L., Chuang S. E., Lin M. T. and Yang S. Y. (2001) The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 20, 677-85. Lagger G., Doetzlhofer A., Schuettengruber B., Haidweger E., Simboeck E., Tischler J., Chiocca S., Suske G., Rotheneder H., Wintersberger E. and Seiser C. (2003) The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 23, 2669-79. Lahmann P. H., Hoffmann K., Allen N., van Gils C. H., Khaw K. T., Tehard B., Berrino F., Tjonneland A., Bigaard J., Olsen A., Overvad K., Clavel-Chapelon F., Nagel G., Boeing H., Trichopoulos D., Economou G., Bellos G., Palli D., Tumino R., Panico S., Sacerdote C., Krogh V., Peeters P. H., Bueno-de-Mesquita H. B., Lund E., Ardanaz E., Amiano P., Pera G., Quiros J. R., Martinez C., Tormo M. J., Wirfalt E., Berglund G., Hallmans G., Key T. J., Reeves G., Bingham S., Norat T., Biessy C., Kaaks R. and Riboli E. (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111, 762-71. Lamboley C., Bringuier A. F. and Feldmann G. (2000) Induction of apoptosis in normal cultured rat hepatocytes and in Hep3B, a human hepatoma cell line. Cell Biol Toxicol 16, 185-200. Lambrinoudaki I., Christodoulakos G., Panoulis C., Botsis D., Rizos D., Augoulea A. and Creatsas G. (2003) Determinants of serum leptin levels in healthy postmenopausal women. J Endocrinol Invest 26, 1225-30. Lang T., Ikejima K., Yoshikawa M., Enomoto N., Iijima K., Kitamura T., Takei Y. and Sato N. (2004) Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor. Biochem Biophys Res Commun 323, 1091-5. Laud K., Gourdou I., Pessemesse L., Peyrat J. P. and Djiane J. (2002) Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188, 219-26. Leu C. M., Chang C. and Hu C. (2000) Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 19, 1665-75. Liao D. J., Natarajan G., Deming S. L., Jamerson M. H., Johnson M., Chepko G. and Dickson R. B. (2000) Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene 19, 1307-17. Liu Y., Ludes-Meyers J., Zhang Y., Munoz-Medellin D., Kim H. T., Lu C., Ge G., Schiff R., Hilsenbeck S. G., Osborne C. K. and Brown P. H. (2002) Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21, 7680-9. Liu Z., Uesaka T., Watanabe H. and Kato N. (2001) High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol 19, 1009-14. Liu Z. J., Endoh A., Li R. and Ohzeki T. (2004) Effects of leptin and dexamethasone on long and short leptin receptor mRNA. Pediatr Int 46, 561-4. Marrero J. A., Fontana R. J., Fu S., Conjeevaram H. S., Su G. L. and Lok A. S. (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42, 218-24. Marttunen M. B., Andersson S., Hietanen P., Karonen S. L., Koistinen H. A., Koivisto V. A., Tiitinen A. and Ylikorkala O. (2000) Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients. Maturitas 35, 175-9. Mawson A., Lai A., Carroll J. S., Sergio C. M., Mitchell C. J. and Sarcevic B. (2005) Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229, 161-73. McTiernan A., Rajan K. B., Tworoger S. S., Irwin M., Bernstein L., Baumgartner R., Gilliland F., Stanczyk F. Z., Yasui Y. and Ballard-Barbash R. (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21, 1961-6. Meissner U., Ostreicher I., Allabauer I., Rascher W. and Dotsch J. (2003) Synergistic effects of hypoxia and insulin are regulated by different transcriptional elements of the human leptin promoter. Biochem Biophys Res Commun 303, 707-12. Menu E., Kooijman R., Van Valckenborgh E., Asosingh K., Bakkus M., Van Camp B. and Vanderkerken K. (2004) Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 90, 1076-83. Michels J., Johnson P. W. and Packham G. (2005) Mcl-1. Int J Biochem Cell Biol 37, 267-71. Misso M. L., Jang C., Adams J., Tran J., Murata Y., Bell R., Boon W. C., Simpson E. R. and Davis S. R. (2005) Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause 12, 210-5. Mitchell K. O. and El-Deiry W. S. (1999) Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 10, 223-30. Mukherjee S. and Conrad S. E. (2005) c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280, 17617-25. O'Brien S N., Welter B. H. and Price T. M. (1999) Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun 259, 695-8. O'Neil J. S., Burow M. E., Green A. E., McLachlan J. A. and Henson M. C. (2001) Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta. Mol Cell Endocrinol 176, 67-75. Ogunwobi O. O. and Beales I. L. (2007) The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 22, 401-9. Okumura M., Yamamoto M., Sakuma H., Kojima T., Maruyama T., Jamali M., Cooper D. R. and Yasuda K. (2002) Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 1592, 107-16. Olsen C. M., Green A. C., Whiteman D. C., Sadeghi S., Kolahdooz F. and Webb P. M. (2007) Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 43, 690-709. Onuma M., Bub J. D., Rummel T. L. and Iwamoto Y. (2003) Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278, 42660-7. Opferman J. T., Iwasaki H., Ong C. C., Suh H., Mizuno S., Akashi K. and Korsmeyer S. J. (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101-4. Oswald F., Lovec H., Moroy T. and Lipp M. (1994) E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene 9, 2029-36. Pai R., Lin C., Tran T. and Tarnawski A. (2005) Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun 331, 984-92. Park H. Y., Kwon H. M., Lim H. J., Hong B. K., Lee J. Y., Park B. E., Jang Y., Cho S. Y. and Kim H. S. (2001) Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33, 95-102. Pavelka J. C., Brown R. S., Karlan B. Y., Cass I., Leuchter R. S., Lagasse L. D. and Li A. J. (2006) Effect of obesity on survival in epithelial ovarian cancer. Cancer 107, 1520-4. Petridou E., Papadiamantis Y., Markopoulos C., Spanos E., Dessypris N. and Trichopoulos D. (2000) Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11, 383-8. Regimbeau J. M., Colombat M., Mognol P., Durand F., Abdalla E., Degott C., Degos F., Farges O. and Belghiti J. (2004) Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 10, S69-73. Reynolds J. E., Yang T., Qian L., Jenkinson J. D., Zhou P., Eastman A. and Craig R. W. (1994) Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 54, 6348-52. Risch H. A. (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90, 1774-86. Roberts L. R. and Gores G. J. (2005) Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25, 212-25. Rodriguez C., Calle E. E., Fakhrabadi-Shokoohi D., Jacobs E. J. and Thun M. J. (2002) Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 11, 822-8. Rose D. P., Gilhooly E. M. and Nixon D. W. (2002) Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 21, 1285-92. Rouet-Benzineb P., Aparicio T., Guilmeau S., Pouzet C., Descatoire V., Buyse M. and Bado A. (2004) Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J Biol Chem 279, 16495-502. Russo V. C., Metaxas S., Kobayashi K., Harris M. and Werther G. A. (2004) Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 145, 4103-12. Sahu A. (2004) Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 145, 2613-20. Saladin R., De Vos P., Guerre-Millo M., Leturque A., Girard J., Staels B. and Auwerx J. (1995) Transient increase in obese gene expression after food intake or insulin administration. Nature 377, 527-9. Saxena N. K., Titus M. A., Ding X., Floyd J., Srinivasan S., Sitaraman S. V. and Anania F. A. (2004) Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. Faseb J 18, 1612-4. Schildkraut J. M., Schwingl P. J., Bastos E., Evanoff A. and Hughes C. (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88, 554-9. Senaris R., Garcia-Caballero T., Casabiell X., Gallego R., Castro R., Considine R. V., Dieguez C. and Casanueva F. F. (1997) Synthesis of leptin in human placenta. Endocrinology 138, 4501-4. Seoane J., Le H. V. and Massague J. (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-34. Sharma D., Saxena N. K., Vertino P. M. and Anania F. A. (2006) Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13, 629-40. Shigemasa K., Katoh O., Shiroyama Y., Mihara S., Mukai K., Nagai N. and Ohama K. (2002) Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn J Cancer Res 93, 542-50. Sierra-Honigmann M. R., Nath A. K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W. C., Madge L. A., Schechner J. S., Schwabb M. B., Polverini P. J. and Flores-Riveros J. R. (1998) Biological action of leptin as an angiogenic factor. Science 281, 1683-6. Smith-Kirwin S. M., O'Connor D. M., De Johnston J., Lancey E. D., Hassink S. G. and Funanage V. L. (1998) Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 83, 1810-3. Somasundar P., Frankenberry K. A., Skinner H., Vedula G., McFadden D. W., Riggs D., Jackson B., Vangilder R., Hileman S. M. and Vona-Davis L. C. (2004a) Prostate cancer cell proliferation is influenced by leptin. J Surg Res 118, 71-82. Somasundar P., McFadden D. W., Hileman S. M. and Vona-Davis L. (2004b) Leptin is a growth factor in cancer. J Surg Res 116, 337-49. Somasundar P., Riggs D., Jackson B., Vona-Davis L. and McFadden D. W. (2003a) Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg 186, 575-8. Somasundar P., Yu A. K., Vona-Davis L. and McFadden D. W. (2003b) Differential effects of leptin on cancer in vitro. J Surg Res 113, 50-5. Sukhotnik I., Vadasz Z., Coran A. G., Lurie M., Shiloni E., Hatoum O. A. and Mogilner J. G. (2006) Effect of leptin on intestinal re-growth following massive small bowel resection in rat. Pediatr Surg Int 22, 9-15. Sutherland R. L. and Musgrove E. A. (2004) Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9, 95-104. Sweeney G. (2002) Leptin signalling. Cell Signal 14, 655-63. Tartaglia L. A. (1997) The leptin receptor. J Biol Chem 272, 6093-6. Tartaglia L. A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G. J., Campfield L. A., Clark F. T., Deeds J., Muir C., Sanker S., Moriarty A., Moore K. J., Smutko J. S., Mays G. G., Wool E. A., Monroe C. A. and Tepper R. I. (1995) Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-71. Tessitore L., Vizio B., Jenkins O., De Stefano I., Ritossa C., Argiles J. M., Benedetto C. and Mussa A. (2000) Leptin expression in colorectal and breast cancer patients. Int J Mol Med 5, 421-6. Uauy R. and Solomons N. (2005) Diet, nutrition, and the life-course approach to cancer prevention. J Nutr 135, 2934S-2945S. Van Gaal L. F., Wauters M. A., Mertens I. L., Considine R. V. and De Leeuw I. H. (1999) Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord 23 Suppl 1, 29-36. Vaque J. P., Navascues J., Shiio Y., Laiho M., Ajenjo N., Mauleon I., Matallanas D., Crespo P. and Leon J. (2005) Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J Biol Chem 280, 1112-22. Wang J., Liu R., Hawkins M., Barzilai N. and Rossetti L. (1998) A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 393, 684-8. Wang X. J., Yuan S. L., Lu Q., Lu Y. R., Zhang J., Liu Y. and Wang W. D. (2004) Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol 10, 2478-81. Wang Y., Kuropatwinski K. K., White D. W., Hawley T. S., Hawley R. G., Tartaglia L. A. and Baumann H. (1997) Leptin receptor action in hepatic cells. J Biol Chem 272, 16216-23. Wei L. H., Kuo M. L., Chen C. A., Chou C. H., Cheng W. F., Chang M. C., Su J. L. and Hsieh C. Y. (2001) The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 20, 5799-809. Weng C., Li Y., Xu D., Shi Y. and Tang H. (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280, 10491-500. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R. and Beach D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-4. Yin N., Wang D., Zhang H., Yi X., Sun X., Shi B., Wu H., Wu G., Wang X. and Shang Y. (2004) Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 64, 5870-5. Yu Q., Geng Y. and Sicinski P. (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-21. Zabeau L., Defeau D., Van der Heyden J., Iserentant H., Vandekerckhove J. and Tavernier J. (2004) Functional analysis of leptin receptor activation using a Janus kinase/signal transducer and activator of transcription complementation assay. Mol Endocrinol 18, 150-61. Zabeau L., Lavens D., Peelman F., Eyckerman S., Vandekerckhove J. and Tavernier J. (2003) The ins and outs of leptin receptor activation. FEBS Lett 546, 45-50. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L. and Friedman J. M. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-32. Zhao A. Z., Huan J. N., Gupta S., Pal R. and Sahu A. (2002) A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 5, 727-8. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29259 | - |
| dc.description.abstract | 摘要
瘦體素為脂肪細胞主要分泌的內泌素之一，可能參與肥胖相關的癌生成與進展，也被視為許多類型癌細胞的生長因子，除了內分泌方式，也可能以旁分泌方式作用於標的組織。較少文獻探討瘦體素於乳癌、卵巢癌與肝癌細胞的作用，本研究乃針對此三類型的癌細胞，研究瘦體素的作用與其傳訊途徑與機制。在所有測試的三類型癌細胞，瘦體素都促進細胞的增生與抗凋亡作用。在促進細胞增生上，瘦體素普遍刺激cyclin D1的表現、進而加速細胞週期的運轉；而在兩種婦癌細胞，一種cyclin D1的轉錄因子c-Myc其表現也被瘦體素刺激。此外，在乳癌細胞中，抑癌因子p53與細胞素依賴性激酶抑制因子p21WAF/CIP1的表現則被瘦體素所減弱，顯示瘦體素也能藉由減弱p53與p21WAF/CIP1的表現以推促細胞週期的運轉。在兩種婦癌細胞細的抗凋亡上，瘦體素主要刺激抗凋亡因子Mcl-1的表現，而在肝癌細胞，則減少凋亡因子Bax的表現；顯然瘦體素抗凋亡的作用機制有細胞類型的差別。在所有測試的三類型癌細胞中，瘦體素的作用皆由JAK2所連接的訊息途徑所傳達，而在JAK2下游必有MEK1/2與ERK1/2（一般構成所謂MEK/ERK1/2的傳訊單位）的參與，形成JAK2-MEK/ERK1/2的傳訊路徑。在肝癌細胞，於JAK2-MEK/ERK1/2的傳訊路徑間另有PI3K與Akt（一般構成所謂PI3K/Akt的傳訊單位）的參與，形成JAK2-PI3K/Akt-MEK/ERK1/2的傳訊途徑；而在乳癌細胞，瘦體素作用的傳訊途徑則為JAK2-PI3K-EK/ERK1/2，瘦體素並不活化Akt。有趣的是，瘦體素分別活化卵巢癌細胞中JAK2-MEK/ERK1/2與PI3K/Akt兩條分明的路徑，雖然PI3K/Akt與JAK2-MEK/ERK1/2之間有訊息交接，彼此卻不為上下游的關係。本研究顯示活化cyclin D1以加速細胞週期運轉為瘦體素促進乳癌、卵巢癌與肝癌細胞增生作用的共同機制，而瘦體素抗凋亡的作用機制則因細胞類型略有不同。在乳癌、卵巢癌與肝癌細胞中，瘦體素作用的的傳訊途徑明顯呈現細胞類型的特異性。 | zh_TW |
| dc.description.abstract | Abstract
Leptin, one of the major hormones synthesized by adipocytes, is involved in the development of obesity associated cancers. It plays as a paracrine/ autocrine regulator mediating growth of various types of cancer cells. Effects of leptin in breast, ovarian and liver cancer cells were less studied, therefore in the present study, we used the three cancer cells to investigate leptin effects and its signaling pathways and mechanisms. In all three examined cancer cells, we found leptin induced cell proliferation and anti-apoptosis. Leptin-stimulated cell proliferation was achieved by provoking expression of cyclin D1 that speeds up cell-cycle progression. In breast and ovarian cancer calls, the expression of c-Myc, one of the transcription factors of cyclin D1 promoter, was enhanced by leptin. In addition, we observed leptin also down-regulated tumor suppressor p53 and cyclin-depedent kinase (CDK) inhibitor p21WAF1/CIP1 to promote cell-cycle progression. In both gynaecological cancer cells, leptin attenuated cell apoptosis by up-regulating expression of antiapoptotic MCL-1. In hepatocellular carcinoma (HCC) cells, the anti-apoptotic effects of leptin were mediated by decreasing expression of proapoptotic Bax. The results indicated the mechanism of leptin-inhibited anti-apoptosis is cell type-specific. In all three cancer cells, the intracellular signals of leptin were transduced by a Janus kinase 2 (JAK2)-linked pathways and at the downstream of JAK2, MEK1/2 and ERK1/2 are involved in the signaling cascade. Besides of JAK2, MEK1/2 and ERK1/2, in HCC cells, PI3K and Akt were participated in the leptin activated signaling pathway. We define that the signaling cascade of leptin in HCC is a JAK2-PI3K/Akt-MEK/ERK1/2. In breast cancer cells, not like in HCC, leptin has no influence on phosphorylation of Akt and leptin-induced signaling pathway is JAK2-PI3K-MEK/ERK1/2. Interestingly, in ovarian cancer cells, crosstalk between two signaling pathways, JAK2-MEK/ERK1/2 and PI3K/Akt, were activated by leptin. Our study demonstrated that in the three examined cancer cells, leptin promotes cell proliferation is generally mediated by stimulating the expression of cyclin D1 to accelerate cell-cycle progression. However the mechanism of leptin on inhibiting apoptosis is cell-specific. The signaling pathways activated by leptin are cell type-dependent. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T01:03:30Z (GMT). No. of bitstreams: 1 ntu-96-F87629001-1.pdf: 3632786 bytes, checksum: 70156cce911623ff2287b503556e12fe (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | Index
摘要………………………………………………………………...1 Abstract…………………………………………………………...2 Introduction……………………………………………………...4 Leptin………………………………………………………...………………...4 Regulation of leptin secretion…………………………………………………4 Leptin receptors………………………..………………………..…………….5 Leptin signaling………………………………………..…………..………..…8 Leptin and obesity……………………………………..……….…………..….8 Leptin and cancers………………………………….......……………..………9 Material & Methods………………………………………………….11 Reagents and antibodies……………..………..…...…………………………11 Cell lines and culture……………..…..……………….……………………....11 RNA extraction and reverse transcription (RT)…………..……...….……...12 Polymease chain reaction (PCR)..……………………..………..…….……...12 MTT assay..…………………….…………………………….…..……………14 Cell number counting…………………………………….…………………...14 Flow cytometry………………………….….………………………………….14 Western blotting analysis………………….………………………………….14 Construction of pCD-1 Luc plasmid………….……………………………...15 Transfection and luciferase activity assay……….…………………………...15 Statistical analysis……………………………………..……………………….16 Part I Effects of leptin in breast cancer cells………..……..17 Introduction………………………………………………………..19 I.1: Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21 WAF1/CIP1………………………………………..…..22 Results…………………………………………………………………..22 Leptin autoregulated expressions of itself and its receptor……..………………..22 Leptin stimulated cell proliferation………………………………..………………22 Leptin stimulated cyclin D1 expression…………………………………..………..23 Leptin inhibited expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1..23 Leptin down-regulated expression of tumor suppressor p53…………….……...23 Leptin up-regulated proto-oncogene c-Myc expression……………….…………24 Leptin stimulated cell proliferation through cross-talk of multiple pathways...24 Effect of cooperation between leptin and estrogen on cell growth……….……..24 Leptin reduced the proportion of G0/G1-phase cell population…………….…..25 Figures……………………………………………………………...…..26 Figure 1. Autoregulation and proliferative effect of leptin………………………26 Figure 2. Leptin regulated expression of cyclin D1, p21 WAF1/CIP1, tumor suppressor p53 and c-Myc………………………………………………………..28 Figure 3. JAK2 inhibitor prevented leptin stimulation……….…………………30 Figure 4. MEK/ERK1/2 inhibitor prevented leptin stimulation..……………….31 Figure 5. PI3K inhibitor prevented leptin stimulation…………..………………32 Figure 6. Effect of cooperation between leptin and estrogen……..……………..33 Figure 7. Leptin reduced G0/G1-phase cell population…………………………34 Figure 8. Hypothesized model of leptin signaling on the growth of human breast cancer cells…………………………………………………………………..…....36 Discussion………..……………………………………..…….……….37 I.2: Leptin stimulates cell growth by inducing expressions of c-Myc and cyclin D1 and prevents apoptosis by inducing antiapoptotic Mcl-1 expression through a JAK2-PI3K-MEK/ERK1/2 signaling pathway…...…43 Results………………………………………………………...………...44 Leptin stimulates MCF-7 and T-47D cell growth.……………………...………....44 Leptin attenuates serum-deprivation induced apoptosis…………………..…….44 Leptin up-regulates c-Myc and cyclin D1 expressions.............................….…….45 Leptin stimulates anti-apoptotic Mcl-1 expression……………………….……....45 Leptin stimulates cell growth through activations of JAK2, PI3K and MEK/ERK1/2……………………………….…………………………………...…45 Figures……………………………..…………………………………..48 Figure 1. Leptin stimulates MCF-7 and T-47D cell growth.……………..……...48 Figure 2. Leptin protect MCF-7 cells from serum deprivation induced apoptosis…………………………………………………………………………..49 Figure 3. Leptin regulates expressions of c-Myc, cyclin D1 and Mcl-1……......50 Figure 4. Pharmacological inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 prevent MCF-7 growth from leptin induction………………………….…….…52 Figure 5. Leptin triggers a JAK2- MEK/ERK1/2 signaling pathway…….…....54 Discussion……………………………………………………….….....56 Part II Effects of leptin in hepatocarcinoma cells……....…...58 Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathways…………………………………………………………….58 Introduction……………………………………..…………………...60 Results………………………………………………………………..62 Hepatic malignant and non-malignant cell lines express leptin receptors.…………………………………………………………………………..62 Leptin promotes cell-cycle progression to stimulate growth of hepatic cells….63 Leptin induces cyclin D1 expression……………………………………………..64 Leptin stimulates cell growth through activations of JAK2, PI3K/Akt and MEK/ERK1/2……………………………………………………………………..65 Leptin activates signaling crosstalks among JAK2, PI3K/Akt and MEK/ERK1/2………………………………………………………………...…...66 JAK2, PI3K/Akt and MEK/ERK1/2 mediate leptin-induced cyclin D1 -dependent cell-cycle progression…………………………..…………..……..…67 Leptin inhibits TGF- b1-induced apoptosis by down-regulating Bax expression………………………………………………………………………….68 Anti-apoptotic effect of leptin goes through activation of JAK2, PI3K/Akt and MEK/ERK1/2………………………...…………………………………………...69 Figures & Tables…...…………………………………………………..70 Figure 1. Expressions of leptin receptors in hepatic cells………………………..70 Figure 2. Leptin stimulates hepatic cell growth………………………………......71 Table 1. Leptin promotes cell cycle progression in Hep3B cells…….……………73 Figure 3. Leptin induces hepatic cyclin D1 expression…………………...………74 Figure 4. Leptin activates phophorylations of JAK2, Akt and ERK1/2 in hepatic cells.............................................................................................................................76 Figure 5. Pharmacological inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 prevent hepatic cell growth from leptin induction……………………………….78 Figure 6. Leptin triggers JAK2-linked PI3K/Akt and MEK/ERK1/2 signaling pathways…………………………………………………………………………….80 Figure 7. Pharmacological inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 prevent hepatic cyclin D1 expression from leptin induction…………………….82 Table 2. Inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 prevent leptin-activated hepatic cell cycle progression…..……...………………...…..84 Figure 8. Leptin protects HCC cells from TGF-b1-induced apoptosis by down-regulating apoptotic Bax expression……………………………….…...85 Figure 9. Inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 withdraw leptin rescue of TGF-b1-induced HCC cell death…………………………..…...…….87 Figure 10. Leptin passes through a JAK2-PIK3/Akt-MEK/ERK1/2 signaling cascade to partially reverse the TGF-b1-reduced Bcl-2/Bax ratio and thus prevent HCC apoptosis…………..……………………………………….……...89 Figure 11. A hypothetic mode underlying somatotropic effect of leptin on HCC cells………………….………………………………………………………..……91 Discussion………..……………………………………………………92 Part III Effects of leptin in ovarian cancer cells......………..99 Leptin stimulates cell growth and anti-apoptosis by inducing expressions of c-Myc, cyclin D1 and Mcl-1 through activations of JAK2- -MEK/ERK1/2 and PI3K/Akt signaling pathways in OVCAR-3 cells………………………99 Introduction…………………………..………………………………...99 Results…………………………………..……………………………...102 Leptin stimulates growth of ovarian cancer cells….………………….…………102 Leptin reduces serum-deprivation induced apoptosis………………….……….102 Leptin induced expressions of cyclin D1, c-Myc and Mcl-1.................................103 Activations of JAK2, PI3K/Akt and MEK/ERK1/2 pathways mediate leptin-stimulated cell growth in OVCAR-3……………………………….…….104 Leptin activates crosstalks among JAK2, PI3K/Akt and MEK/ERK1/2 signaling pathways…………………………….…………………………………………….104 Figures……………………………………………………………...106 Figure 1. Leptin stimulates growth of ovarian cancer cells....……..………..106 Figure 2. Leptin protects OVCAR-3 cells from serum deprivation induced apoptosis………………………………………...………………………….…..107 Figure 3. Leptin up-regulates expressions of cyclin D1 and Mcl-1 …..…..…107 Figure 4. Leptin acutely induces c-Myc expression in OVCAR-3 cells..…....108 Figure 5. Leptin induces Mcl-1 expression in two phases in OVCAR-3 cells.109 Figure 6. Leptin activates phophorylations of JAK2, Akt and ERK1/2 in OVCAR-3 cells…………………………………………………..……………...110 Figure 7. Pharmacological inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 prevent ovarian cancer cell growth from leptin induction……………....…....112 Figure 8. Leptin triggers JAK2-MEK/ERK1/2 and PI3K/Akt signaling pathways..........................114 Discussion…..………………………………………………..………116 Conclusions…………………………………….………….……....118 References…………………………………………………….…....120 | |
| dc.language.iso | en | |
| dc.subject | 細胞生長 | zh_TW |
| dc.subject | 肝腫瘤 | zh_TW |
| dc.subject | 卵巢癌 | zh_TW |
| dc.subject | 瘦體素 | zh_TW |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | cell growth | en |
| dc.subject | leptin | en |
| dc.subject | breast cancer | en |
| dc.subject | hepatocellular carcinoma | en |
| dc.subject | ovarian cancer | en |
| dc.title | 瘦體素對內分泌相關腫瘤細胞生長與凋亡之作用機轉 | zh_TW |
| dc.title | Mechanisms of Leptin Effects on Growth and Apoptosis of Endocrine-Related Cancer Cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 楊性芳,朱瑞民,張繼堯,劉振軒,林中天 | |
| dc.subject.keyword | 瘦體素,乳癌,肝腫瘤,卵巢癌,細胞生長, | zh_TW |
| dc.subject.keyword | leptin,breast cancer,hepatocellular carcinoma,ovarian cancer,cell growth, | en |
| dc.relation.page | 132 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-24 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 3.55 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。